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In 2018, a total of 90 original scientific papers or
reviews were published in Acta Cardiologica.
In this paper, we focus on the 10 best papers that
we selected based upon the innovative character and/
or upon the clinical relevance of their research. In dif-
ferent domains of the cardiology, we highlight the
most important findings from these 10 best
research papers.
1. Hypertrophic cardiomyopathy
Risk assessment for sudden cardiac death (SCD) in
hypertrophic cardiomyopathy is a crucial part in the
management as there is a subgroup at increased risk
of SCD (up to 4–6% per year) for whom implantable
cardioverter defibrillator (ICD) is recommended.
Current risk models, although useful, remain imprecise.
Dr Patel et al. from the Mayo Clinic assesses electro-
cardiogram-derived risk factors on SCD in a 1615 HCM
patients with an ICD and related this to SCD events as
documented on the ICD [1]. They identified prolonged
QTc as an important ECG related risk factor for SCD
and death even when controlling for typical risk fac-
tors (see Figure 1).
The management for HCM does not only include
an appropriate indication for ICD but targets also the
treatment of the obstruction caused by asymmetrical
septal hypertrophy which is present in one-third of
the HCM patients. Intracavitary gradient can be
reduced by medication, by alcohol septal ablation or
by surgical myectomy. Dr Hoedemakers et al. evalu-
ates the long-term effects of these three strategies in
106 HOCM patients (27% conservative, 24% alcohol
ablation, 49% myectomy) during a follow-up period of
8 ± 5 years [2]. Conservative treatment was associated
with more SCD-related events (5%/year vs 1%/year in
the invasively treated patients) (see Figure 2). Invasive
treatment was associated with a higher need for pace-
maker implantation.
2. Heart failure
Sacubitril/valsartan reduced heart failure (HF) hospital-
isation and mortality in the PARADIGM-HF trial. The
group of Dr Mullens studied the effect of this drug in a
real-world population of 201 HF patients [3,4].
Although their patients were frailer and older than in
the landmark trial, the initiation of this drug exhibits a
significant and early reduction in incident HF-hospital-
isation (as compared to antecedent HF-admissions)
together with a significant symptomatic and functional
improvement (see Figure 3). Also, higher doses seem to
be associated with more reductions in HF-admissions,
underscoring the importance of dose uptitration.
In ischaemic cardiomyopathy, it is unclear whether
the presence of chronic total occlusion (CTO) carries a
higher risk for ventricular arrhythmia (VA) and mortal-
ity in patients with an ICD. Dr Vutthikraivit et al. per-
formed a meta-analysis to examine the association
between the presence of CTO and poor cardiovascular
outcome in patients with ischaemic cardiomyopathy
with an implanted ICD [5]. Based upon five studies,
including 1095 patients (505 with CTO), the presence
of CTO was associated with an increased risk of VA
(risk ratio 1.7) and of all-cause mortality (risk ration
1.6). These findings suggest revascularisation of CTO
should be considered in these patients.
Risk stratification of heart failure is mainly based upon
patient-related factors (such as extent of cardiac dysfunc-
tion, presence of renal failure); but, it is less known
CONTACT Marc J. Claeys marc.claeys@uantwerpen.be Department of Cardiology, Antwerp University Hospital, Wilrijkstraat 10, B-2650
Edegem, Belgium
 2019 Belgian Society of Cardiology
ACTA CARDIOLOGICA
2020, VOL. 75, NO. 5, 383–387
https://doi.org/10.1080/00015385.2019.1611190
whether environment factors such as air pollution might
play a role. Chen et al. studied whether the exposure of
particulate matter (PM2.5) might aggravate heart failure
in a murine model of transverse aortic constriction-
induced left ventricular failure (TAC) [6]. Exposure to
PM2.5 decreased the LV-function and augmented the
associated pulmonary arterial hypertension as compared
to the sham operation (see Figure 4). Even in sham
Figure 1. Impact of prolonged QTc on overall survival.
Figure 2. Sudden cardiac death related event rate.
Figure 3. Heart failure hospitalisations before and after sacubitril/valsartan in a similar timeframe.
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group, exposure to PM 2.5 resulted in a decrease of
LV function.
3. Valvular heart disease
Transcatheter aortic valve implantation (TAVI) is the
preferred treatment modality for patient with severe
aortic stenosis (AS) at high or prohibitive risk for surgi-
cal aortic valve replacement. Dr Bakelants et al. aimed
to evaluate real-world outcomes of 405 high-risk AS
patients according to the treatment strategy chosen
within the heart-team: TAVI (n¼ 188) vs surgical aortic
valve replacement (SAVR, n¼ 98) vs medical treatment
(MT, n¼ 116) [7]. SAVR patients had lower surgical risk
score than TAVI and MT patients. At 1 year, all-cause
mortality was 14% for SAVR, 17% for TAVI and 51%
for MT (p< 0.001) (Figure 5). Hospital stay was shorter
with TAVI vs SVAR and safety at 30% favoured TAVI
(22% vs 47%).
Dr Kanjanahattakij et al. performed a systematic
review and meta-analysis to determine the relationship
between pre-procedural anaemia and mortality post-
TAVI [8]. Based on six studies, the authors found an
independent association between anaemia and long-
term mortality (adjusted RR 1.43) but not for short-term
mortality (see Figure 6). Further study is needed to
explore the underlying pathophysiology of this
association.
4. Atrial fibrillation
Non-valvular atrial fibrillation (NVAF) carries a risk of
ischaemic stroke or systemic embolism, which can be
mitigated using anticoagulant treatment. Dr Cools et al.
describes treatment patterns in anticoagulant therapy
in 1713 patients with a new diagnosed NVAF in the
period 2012–2016 (Belgian results from the GARFIELD-
AF registry, see Figure 7) [9]. Guidelines adherence to
stroke prevention was higher in Belgium than in the
rest of Europe (80% vs 73%). In high stroke risk patients
(CHADS-VASc  2), anticoagulants were used in 84.3%,
whereas in low-risk patients (CHADS-VASc 0-1) anticoa-
gulants were overused (58.7%).
AP: antiplatelet; DTI: direct thrombin antagonist;
FXa: factor Xa inhibitor; VKA: vitamin-K-antagonist.
5. Ischaemic heart disease
Platelet inhibition with the newer more potent anti-
platelet drugs (ticagrelor, prasugrel) was superior
Figure 4. LV ejection fraction.
Figure 5. Clinical outcome and treatment strategy.
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than clopidogrel when evaluated in terms of major
adverse clinical events (MACE) in acute coronary syn-
dromes patients. The role of new antiplatelets on top
of aspirin with respect to minor myocardial injury
after elective PCI has not been established previously.
G€oks€ul€uk et al. compare post PCI myonecrosis in 104
patients receiving clopidogrel with 96 patients
receiving ticagrelor [10]. In this randomised trial,
minor myocardial necrosis was significantly more
prevalent in clopidogrel than in the ticagrelor group
(33% vs 19%). MACE rate at 1 month (myocardial
infarction, stroke and transient ischaemic attack,
death) was also higher in the clopidogrel group (16%
vs 6%).
Figure 6. Association between anaemia and long-term mortality.
Figure 7. Antithrombotic therapy at baseline according to CHA2DS2-VASc score.
Figure 8. Troponine increase after exercise.
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Cardiac troponins play a crucial role in the diagno-
sis of acute myocardial infarction. However, high sensi-
tive cardiac troponin (HsTn) levels can be elevated
due to non-pathological evens such as strenuous exer-
cise. Dr Unl€u et al. evaluated the effect of statins on
hsTnT level with moderated exercise in healthy sub-
jects [11]. Statin therapy causes a significant trop
increase, whereas the increase in the control group
was marginal (see Figure 8). The observed increase
can jeopardise the accuracy of clinical diagnosis par-
ticularly in the 0–1 h diagnostic protocols.
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